| Scleroderma Clinical Trials (MAIN MENU) | |
|
| Scleroderma Clinical Trials: Current Studies, Open Enrollments |
|
|
| Overview of Scleroderma Clinical Trials and Treatments |
| Systemic Scleroderma Symptoms. At present, there are no proven treatments or cure for any forms of scleroderma. However, there are effective therapies for many of the symptoms as well as clinical trials for specific scleroderma related symptoms. ISN. (Also see: What is Scleroderma and Types of Scleroderma) |
| |
| Treatment of complications associated with systemic sclerosis. Systemic sclerosis is characterized by various circulatory, dermatological, gastrointestinal, musculoskeletal, pulmonary, and renal complications. Although there is no cure for systemic sclerosis, management of its associated complications can help improve patients' quality of life. (PubMed) Am J Health Syst Pharm. 2008 Feb 15; 65(4):315-21. |
| Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis |
| |
| ASTIS Study |
| ASTIS Study: High Dose Immunoablation and Hematopoietic Stem cell Transplantation versus Monthly Intravenous Pulse Therapy Cyclophosphomide in Severe Systemic Sclerosis. ISN. |
| Bosentan, Tracleer |
| Bosentan (Tracleer) appears to be beneficial for a variety of scleroderma symptoms, such as digital ulcers, pulmonary fibrosis, pulmonary hypertension, and skin fibrosis. ISN. |
| |
| Cyclophosphamide (Cytoxan ®) and Revimmune |
| Current Studies, Initial Results Positive |
| Cyclophosphamide (Cytoxan) and Revimmune for Scleroderma Lung Disease. Clinical trial and research information on cyclophosphamide for pulmonary alveolitis. ISN. |
| Imatinib Mesylate (Gleevec) |
| Current Studies, Open Enrollment, Initial Results Positive, 2008 |
| Imatinib Mesylate (Gleevec) Clinical Trials for Systemic Scleroderma. Imatinib mesylate (Gleevec) is currently used for certain forms of leukemia, and is now in the following clinical trials for safety and efficacy for systemic scleroderma. ISN. |
| Pulmonary Fibrosis with Systemic Sclerosis |
| Open Enrollment, 2008 |
| Recruiting is taking place for a multi-center placebo controlled research study for pulmonary fibrosis with systemic sclerosis sponsored by Novartis Pharmaceuticals. Male and female patients, 18 to 65 years of age may be eligible for participation. |
| Interested patients can contact the Medical College of Wisconsin (414-456-7019), University of Houston (713-500-7118), UCLA (310-825-4744), Boston University (617-638-4344) or at John Hopkins University (410-550-8582) in Baltimore, Maryland. Novartis Pharmaceuticals. Posted 01-04-08. (Also see: Pulmonary Fibrosis and What is Scleroderma?) |
| SCOT Trial |
| Open Enrollment, 2005-2008 |
| SCOT Clinical Trial, which stands for "Scleroderma Cyclophosphamide Or Transplantation", will compare two potential therapies: autologous stem cell transplantation versus high-dose monthly cyclophosphamide. Study dates 2005-2008. (Also see: Cyclophosphamide, Cytoxan and Stem Cell Transfusion) |
| High Dose Cyclophosphamide (CYC) Without Stem Cell Transplantation in Systemic Sclerosis. High dose CYC without stem cell transplantation leads to rapid improvement of the modified Rodnan skin, HAQ, and PGA scores in the severe early diffuse SSc. Christopher V. Tehlirian. 689 ACR 2006. (Also see: Cytoxan, ASTIS Clinical Trial, and Skin Fibrosis) |
| Sildenafil Citrate (Viagra) for Pulmonary Hypertension |
| Continuing Studies, Positive Results |
| Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease. SLx-2101 is a novel, long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's. Digital50. Surface Logix Inc. 06/28/07. (Also see: Raynaud's Treatments) |
| (Also see: Pulmonary Hypertension) |
| Stem Cell Transplants for Scleroderma |
| Continuing Studies, Open Entrollment |
| Stem Cell Transplants (Bone Marrow Transplants) for Early Diffuse Scleroderma. ISN. |
| |
| Twins and Siblings With and Without Autoimmune Diseases |
| Open Enrollment (A 5-year study) |
 Families with Twins or Siblings where one has Systemic Rheumatic Disorders (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Lupus, Scleroderma, or Myositis) and one does not. The goal of study 03-E-0099 is to assess why one twin or sibling developed disease and why the other brother or sister did not.
The siblings may or may not be twins, but must be of the same gender and be within a 3-year age difference. Biological parents, or, in some cases, children, will also be included in the study.
Families may enroll at the NIH Clinical Center in Bethesda, Maryland, just 9 miles north of Washington, DC or at their local physician’s office. Transportation assistance may be available and there is no charge for study-related evaluations and medical tests.
For information on the study, call the NIH patient recruiting office toll free at 1-800-411-1222 (For TTY: 1-866-411-1010). National Institutes of Health Clinical Center (NIH). 11/25/05. (Also see: Scleroderma Research Registries and Causes of Scleroderma: Genetics) |
| See Also |
Sjögren's Treatments & Clinical Trials
Scleroderma Medical News
Scleroderma Symptoms (treatments are listed for each symptom) |
